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Introduction {#jth12958-sec-0001}
============

Hemophilia B is a coagulation factor deficiency resulting from reduced levels or an absence of factor IX. Symptoms of recurrent prolonged bleeding result from reduced levels or an absence of plasma FIX, whose function is to cleave and activate FX within the coagulation cascade. FIX is a vitamin K‐dependent plasma protease that participates in the intrinsic blood coagulation pathway. FIX circulates as a zymogen, and is activated to activated FIX (FIXa) by sequential cleavage at p.Arg191‐Ala192 and p.Arg226‐Val227 by activated FXI or tissue factor--activated FVII. With activated FVIII as a cofactor providing correct orientation, FIXa cleaves FX at p.Arg182--Ser183 and p.Arg234--Ile235, resulting in its activation.

The disorder affects approximately one in 30 000 males worldwide. It was discriminated from hemophilia A around 1950, and named Christmas disease by Biggs *et al*. [1](#jth12958-bib-0001){ref-type="ref"}; Christmas was the family name of their first affected individual examined in detail. Patients are classified as having severe (\< 1 IU dL^−1^), moderate (1--5 IU dL^−1^) or mild (5--40 IU dL^−1^) hemophilia B, according to residual FIX activity (FIX:C). The US Universal Data Collection (UDC) database and the UK Haemophilia Centre Doctors' Organization (UKHCDO) annual report for 2013--2014 describe 3785 (UDC) and 1205 (UKHCDO) patients as having mild (26--45%), moderate (21--38%) and severe (34--36%) hemophilia B [2](#jth12958-bib-0002){ref-type="ref"}, [3](#jth12958-bib-0003){ref-type="ref"}.

The gene encoding FIX (*F9)* was cloned in 1982--1983, and its full sequence was published in 1985 [4](#jth12958-bib-0004){ref-type="ref"}. Molecular genetic analysis using linkage analysis to follow the affected allele in hemophilia B families and of mutations responsible for the disorder to facilitate carrier status determination and prenatal diagnosis (PND) became available from this time. *F9* comprises eight exons, with a 2780‐bp transcript encoding a 461‐residue pre‐pro‐protein, which is subsequently cleaved to the 421‐residue mature FIX serine protease.

Although the prevalence of hemophilia B is generally stated as being one in 30 000 males, reported rates in different countries vary widely, and probably partly depend on the level of healthcare provision. In a survey using World Federation for Hemophilia data, the prevalence of hemophilia B per 100 000 males in 103 countries ranged from 0.01 (Nigeria) to 8.07 (Ireland) [5](#jth12958-bib-0005){ref-type="ref"}.

The recently revised *F9* locus‐specific mutation database (*F9*db) lists \> 3000 pathogenic mutations and neutral polymorphisms, with mutations affecting 73% of the 461 residues [6](#jth12958-bib-0006){ref-type="ref"}, [7](#jth12958-bib-0007){ref-type="ref"}. The addition of FIX molecular models for missense changes adds useful information about specific substitutions.

The aim of this review is to summarize the current understanding of hemophilia B symptoms in males and carrier females, and its mutation detection, molecular pathology and pathogenicity assessment for diagnostic and prognostic use.

Nomenclature {#jth12958-sec-0002}
============

Gene names and nucleotide and protein changes all follow standard formats. Gene names are defined by the Human Genome Organization (HUGO) Gene Nomenclature Committee (HGNC) [8](#jth12958-bib-0008){ref-type="ref"}, according to which the gene encoding FIX is designated *F9*; nucleotide and protein variants are described according to Human Genome Variation Society (HGVS) nomenclature [9](#jth12958-bib-0009){ref-type="ref"}. Nucleotides and proteins are numbered from the protein initiator methionine; c. denotes cDNA numbering, and p. denotes protein numbering. The HGVS website provides examples highlighting the reporting of different mutation types. The *F9* mutation database (*F9*db) uses HGVS nomenclature plus legacy numbering to facilitate reference to historically reported mutations [6](#jth12958-bib-0006){ref-type="ref"}, [7](#jth12958-bib-0007){ref-type="ref"}. Legacy protein numbering was from the start of mature FIX (HGVS codon 47), and is presented in this article in parentheses. Stable reference sequences known as locus reference genomic (LRG), which should not change over time, are available for *F9*; transcript ID LRG_556t1, and protein ID LRG_556p1 [10](#jth12958-bib-0010){ref-type="ref"}.

*F9*db {#jth12958-sec-0003}
======

The first version of the *F9*db was published in 1990 by Giannelli *et al*. [11](#jth12958-bib-0011){ref-type="ref"}. It described 216 mutations spanning from c.‐49T\>A (legacy --20) to c.1369A\>T (legacy 31 352). Following several annual publications, an internet database was initiated in 1997, but it was last updated in 2004 [12](#jth12958-bib-0012){ref-type="ref"}, and was recently replaced by the current database [6](#jth12958-bib-0006){ref-type="ref"}, [7](#jth12958-bib-0007){ref-type="ref"}. Mutation data were extracted from the *F9*db with query tools, or were kindly provided by P.M. Rallapalli (personal communication, 25 November 2014) for 3656 or 3713 patients.

Hemophilia phenotype {#jth12958-sec-0004}
====================

Phenotype in affected males {#jth12958-sec-0005}
---------------------------

Hemophilia B symptoms include prolonged bleeding and easy bruising. Bleeding into joints and sometimes muscles can occur, accompanied by pain and swelling. Bleeding can be from the nose, can result from cuts, tooth extraction, surgery, or trauma, may continue for a prolonged period, and can restart after stopping. Bleeding can affect the gastrointestinal and urinary tracts. Spontaneous bleeding generally only affects severely/moderately affected patients, who will often experience their first bleed during their first 2 years, with the first bleed sometimes occurring after circumcision. In contrast, mildly affected males may not be diagnosed until later in life.

Hemophilia B severity {#jth12958-sec-0006}
---------------------

There has been some speculation that the symptoms of hemophilia B may be less severe than those of hemophilia A [13](#jth12958-bib-0013){ref-type="ref"}. A recent study of children with severe and moderate hemophilia A (*n* = 679) and hemophilia B (*n* = 123) showed that there was no significant difference in bleeding between patients with the two disease types during their first 75 exposure days [14](#jth12958-bib-0014){ref-type="ref"}. The factors compared included age at first bleed, age at diagnosis, and age at first exposure to factor concentrate. A study of older individuals examining the rate of joint arthroplasty [15](#jth12958-bib-0015){ref-type="ref"} found that the risk of arthroplasty was higher among patients with severe hemophilia A than among those with severe hemophilia B, with a hazard ratio of 2.65, and a 95% confidence interval of 1.62--4.33 (*P* \< 0.001). Results were adjusted for age, hepatitis C virus, human immunodeficiency virus and inhibitor status in a Cox regression model. Schulman [16](#jth12958-bib-0016){ref-type="ref"} used a hemophilia severity score combining annual joint bleed incidence, orthopedic joint score and concentrate consumption, and collected data between 1990 and 1999 on 100 adult and adolescent patients with hemophilia of all severities without an inhibitor history to document bleeding. Scores from 0 to 0.94 were higher in patients with severe hemophilia A than in those with severe hemophilia B (medians of 0.50 and 0.24; *P* = 0.031). The higher prevalence of missense mutations in hemophilia B provides biological evidence for it having lower severity than hemophilia A, although clinical evidence is limited.

Phenotype in female carriers {#jth12958-sec-0007}
----------------------------

Plug *et al*. reported postal survey data on females from hemophilia families in The Netherlands who were carriers or non‐carriers of hemophilia A or hemophilia B [17](#jth12958-bib-0017){ref-type="ref"}. The median FIX:C was 60 IU dL^−1^ (range, 5--219 IU dL^−1^) in carriers, and 102 IU dL^−1^ (range, 45--328 IU dL^−1^) in non‐carriers. For those with FIX:C levels of \> 60 IU dL^−1^, 41--60 IU dL^−1^, and \< 40 IU dL^−1^, a significant trend in number of events when bleeding occurred was observed for bleeding from small wounds and following surgery or tooth extraction.

The relative bleeding risk demonstrated that bleeding following dental extraction or tonsillectomy/adenoidectomy was elevated in carriers as compared with non‐carriers, with relative risks of 23.1 (3.1--169) for dental extraction and 9.9 (1.3--76.3) following tonsillectomy/adenoidectomy.

Sharathkumar *et al*. reported on phenotypic variability in hemophilia B carriers from a large Amish pedigree with a p.Thr342Met mutation (male levels in the *F9*db of \< 1--16 IU dL^−1^). Among up to 64 females, menorrhagia (47%), bruising (31%) and epistaxis (17%) were the most common symptoms. FIX:C levels ranged between 13 IU dL^−1^ and 112 IU dL^−1^. Those with lower FIX:C levels (mean, \~ 35--45 IU dL^−1^) had significantly more subcutaneous hematoma, bleeding following dental extraction, postpartum hemorrhage and surgical bleeding than those with higher levels (mean, \~ 53--64 IU dL^−1^) [18](#jth12958-bib-0018){ref-type="ref"}.

Mutation detection {#jth12958-sec-0008}
==================

Several organizations recommend that mutation analysis should be performed for all patients with hemophilia, highlighting any excess risk of inhibitor development associated with specific mutations, and enabling carrier testing for female relatives and prenatal or possibly preimplantation genetic diagnosis. The first hemophilia B mutation was reported in 1985 [19](#jth12958-bib-0019){ref-type="ref"}. Mutation analysis generally uses PCR DNA amplification followed by Sanger sequencing of the eight exons, the 5′‐untranslated region, the 3′‐untranslated region and splice boundaries of *F9*. In some laboratories, mutation scanning is used to highlight the amplicon containing a candidate mutation prior to its sequence analysis [20](#jth12958-bib-0020){ref-type="ref"}. Next‐generation DNA sequencing (NGS) is also being used to determine the *F9* sequence [21](#jth12958-bib-0021){ref-type="ref"}. Variants comprise point mutations, deletions, insertions, duplications, insertions and deletions, complex changes, and neutral polymorphisms; the proportions currently in the *F9*db [7](#jth12958-bib-0007){ref-type="ref"} are shown in Fig. [1](#jth12958-fig-0001){ref-type="fig"}. The largest proportion of patients with hemophilia B have missense mutations (65%).

![Factor IX mutation type distribution in patients with hemophilia B on the *F9* mutation database. Three thousand six hundred and fifty‐six mutations (P.M. Rallapalli, personal communication) are broken down by type in the larger pie chart. Point mutations are broken down by type in the smaller pie chart. ND, mutation type not determined.](JTH-13-1184-g001){#jth12958-fig-0001}

Large deletions of an exon or more constitute \~ 2% of all unique mutations. They are readily detected in affected males through lack of amplification of one or more exons. Large duplication of an exon or more has only been reported in one hemophilia B case [22](#jth12958-bib-0022){ref-type="ref"}, and, although such mutations are likely to be rare, they may be under‐reported, as a technique that is sensitive to the number of *F9* copies (dosage analysis), such as multiplex ligation‐dependent probe amplification, is required for their identification, but is not in common use. Dosage analysis is required to determine female carrier status for large deletion mutations, and in males and females to identify large duplications [23](#jth12958-bib-0023){ref-type="ref"}, [24](#jth12958-bib-0024){ref-type="ref"}, [25](#jth12958-bib-0025){ref-type="ref"} (Fig. [2](#jth12958-fig-0002){ref-type="fig"}).

![*F9* gene dosage analysis using multiplex ligation‐dependent probe amplification (MLPA). MLPA probes include those for normalization across the genome (control) and for *F7*,*F8*, and *F9*. (A) Dosage in a female lacking a large deletion. (B) Dosage in a female with complete *F9* deletion. (C) Dosage in a female with a partial *F9* deletion of exons 7--8.](JTH-13-1184-g002){#jth12958-fig-0002}

Complex mutations include large deletion and insertion mutations, e.g. a deletion of 4.4 kb from exons 4--6, and its replacement by a 47‐bp sequence [26](#jth12958-bib-0026){ref-type="ref"}, and interruption of the coding sequence by insertion of the mobile genetic element *Alu* into exon 5 in two different patients [27](#jth12958-bib-0027){ref-type="ref"}, [28](#jth12958-bib-0028){ref-type="ref"}, and by a long interspersed nuclear element insertion into exon 7 [29](#jth12958-bib-0029){ref-type="ref"}.

Splice site mutations constitute 212 of 3196 (6.6%) database entries (P.M. Rallapalli, personal communication). Most are within ± 7 nucleotides of the splice site, and much smaller numbers are within ± 25 bp. However, a handful of *F9*db mutations lie deeper in introns, with c.392‐569C\>A in intron 4 having been reported in severe hemophilia B (unpublished); however, these variants have not been validated as causing the disorder. Deep intronic mutations are rarely reported in hemophilia B [30](#jth12958-bib-0030){ref-type="ref"}, but are not routinely sought.

Chaivali *et al*. described hemophilia B as being 'a quasi‐quantitative condition with certain mutations showing phenotypic plasticity' [31](#jth12958-bib-0031){ref-type="ref"}. By the use of unsupervised learning computational analysis of 201 missense mutations in the *F9*db with two or more reports, mutations were divided into three clusters. Mutations in clusters 1 and 2 showed FIX:C level variation, whereas cluster 3 mutations had a uniform phenotype. Mutations associated with variable phenotypes were located at residues that were less conserved across species, with fully conserved residues being present in 27% of cluster 1 and 30% of cluster 2, but in 61% of cluster 3.

Analysis of *F9* mRNA {#jth12958-sec-0009}
---------------------

*F9* cDNA reverse‐transcribed from mRNA could provide a good source of material for understanding the effects of splicing defects, and also for the small group of patients with hemophilia B in whom mutations have not been identified by *F9* genomic DNA examination. In contrast to hemophilia A, few studies have been published on *F9* cDNA analysis. It appears challenging in some instances to obtain full‐length *F9* cDNA from peripheral leukocytes. Sarkar *et al*. analyzed *F9* mRNA by using single‐strand conformation polymorphism, but did not highlight difficulties in obtaining mRNA [32](#jth12958-bib-0032){ref-type="ref"}, and van der Water *et al*. [33](#jth12958-bib-0033){ref-type="ref"} sequenced leukocyte exon 2--4 transcript in wild‐type and mutant to identify an intron 2 splice mutation. Green *et al*. could only obtain a partial transcript of exons 7--8 from leukocytes, in contrast to liver‐derived *F9* mRNA, where the entire transcript was present [34](#jth12958-bib-0034){ref-type="ref"}; similarly, Cutler *et al*. [35](#jth12958-bib-0035){ref-type="ref"} reported leukocyte transcripts from exons 1--2 and 7--8, but not from central *F9* exons. Cao *et al*. recently reported using mRNA analysis to help identify an intron 3 (c.278‐3A\>G) splice defect, and obtained the sequence of the additional intron 3 nucleotides incorporated into the transcript by the mutation [36](#jth12958-bib-0036){ref-type="ref"}. It is possible that transcripts expressed ectopically in cells not from the main site of FIX synthesis may produce mRNA lacking certain exons. The genome browser Ensembl [10](#jth12958-bib-0010){ref-type="ref"} lists three *F9* transcripts with between four and eight exons. It may be worth revisiting the analysis of *F9* leukocyte mRNA for patients in whom mutations have not yet been detected, or to apply NGS to the entire *F9* locus, as undertaken for *F8* [37](#jth12958-bib-0037){ref-type="ref"}, [38](#jth12958-bib-0038){ref-type="ref"}, [39](#jth12958-bib-0039){ref-type="ref"}.

Mutation detection rate {#jth12958-sec-0010}
-----------------------

In 21 studies undertaken from 1993 to 2014 with 20 or more unrelated patients with hemophilia B, *F9* mutation detection rates varied from 83% to 100% in genetic analysis using PCR and Sanger sequencing with occasional dosage analysis. The mean mutation detection rate in the 1811 individuals in these studies was 97.4% (Table S1). Additionally, the UKHCDO Genetic Testing Network collected mutation detection rates of 724 apparently unrelated patients for analysis undertaken to 2010 [20](#jth12958-bib-0020){ref-type="ref"}. Mutations were identified in 704 cases (97.2%), but sensitivity varied by FIX:C level. Mutations were detected in 99.5% of severe cases and in 98.2% of patients with FIX:C of \< 40 IU dL^−1^; individuals with higher levels included most of those with no mutation identified.

*De novo F9* mutations {#jth12958-sec-0011}
----------------------

Eleven of the above studies examined whether there were one or more reported hemophilic patients among the families analyzed, to estimate sporadic case frequency. A study on sporadic mutation prevalence was included [40](#jth12958-bib-0040){ref-type="ref"}. Of 773 patients, 380 were classed as having familial hemophilia B (49%; range, 31--67%), the lowest prevalence being in Ireland [41](#jth12958-bib-0041){ref-type="ref"} and the highest in the USA [42](#jth12958-bib-0042){ref-type="ref"} and Iran [43](#jth12958-bib-0043){ref-type="ref"}.

Causes of reduced FIX levels in symptomatic females {#jth12958-sec-0012}
===================================================

Approximately 10--15% of hemophilia carriers experience bleeding symptoms. Skewed X‐chromosome inactivation (Lyonization) is implicated in some cases, but chromosome translocation, compound heterozygosity for two different mutations and Turner syndrome (XO) can also result in bleeding. Orstavik *et al*. examined 15 hemophilia B carriers; there was no tendency for there to be skewed X‐chromosome inactivation in those with high or low FIX:C levels [44](#jth12958-bib-0044){ref-type="ref"}. Di Michele *et al*. reported on bleeding symptoms and phenotype in US hemophilic females, identified through the UDC database. Of six affected females with hemophilia B (one severe; five moderate), each with a missense mutation, three had skewed X‐chromosome inactivation, and one had a *de novo* X‐chromosome deletion; the reason for hemophilia B was not characterized in two individuals [45](#jth12958-bib-0045){ref-type="ref"}.

Mosaicism {#jth12958-sec-0013}
=========

Somatic and gonadal mosaicism for hemophilia B (the existence of two or more cell lines in an individual with different genotypes) has been reported occasionally. Sommer *et al*. reported on 414 hemophilia B families among whom hemophilia B origin was identified in 49 families by sequencing and haplotype analysis. No 'mutation origin' individuals passed on the affected allele to more than one child, but, in four individuals, the mutant sequence was visible on sequence traces (sensitivity down to \~ 10%), 11% demonstrating somatic mosaicism, suggesting that this is not uncommon [46](#jth12958-bib-0046){ref-type="ref"}. Additionally, the maternal grandmother of a patient had an approximately 50 : 50 ratio of mutant/wild‐type sequence in her leukocyte DNA, and transmitted the same allele to five daughters, only one of whom carried the *F9* mutation [47](#jth12958-bib-0047){ref-type="ref"}. Green *et al*. [48](#jth12958-bib-0048){ref-type="ref"} sought evidence of gonadal mosaicism in 47 families, but detected no ovarian mosaicism, suggesting that the risk of a 'non‐carrier' mother transmitting the mutation to a further child was \< 0.062. The origin of mosaic conditions in hemophilia has been reviewed by Kasper *et al*. [42](#jth12958-bib-0042){ref-type="ref"}, and that of mosaicism in general by Biesecker *et al*. [49](#jth12958-bib-0049){ref-type="ref"}.

Prenatal diagnosis {#jth12958-sec-0014}
==================

PND became available for hemophilia B in the mid‐1980s, when single‐nucleotide variants (SNVs) in *F9* were identified, and became more useful as further genetic markers throughout *F9* were found [50](#jth12958-bib-0050){ref-type="ref"}, [51](#jth12958-bib-0051){ref-type="ref"}, [52](#jth12958-bib-0052){ref-type="ref"}. From the early 1990s, DNA sequencing was increasingly used to determine the familial mutation, and the majority of carrier status determination and PND is now undertaken with this analysis. However, a mix of linkage and sequence analysis can be used to provide a cost‐effective approach to carrier analysis and PND [53](#jth12958-bib-0053){ref-type="ref"}. Early PND at 11--14 weeks of gestation, amniocentesis at 16--18 weeks, and late gestation analysis at ≥ 32 weeks, also using amniocentesis, are all available, the last to inform delivery management for known carriers [54](#jth12958-bib-0054){ref-type="ref"}. Examination of free fetal DNA in the maternal circulation is being used increasingly for early fetal sex determination, and can be utilized from \~ 10 weeks of gestation to avoid invasive PND analysis [55](#jth12958-bib-0055){ref-type="ref"}.

The Italian hemophilia B database records mutations in 373 unrelated patients, and this information has identified 274 carriers of childbearing age. Of 66 PNDs undertaken for 52 hemophilia B carriers (mean age, 34 years; range, 22--44 years), 44 (85%) had received genetic counseling prior to pregnancy, and eight presented once they were pregnant (15%). Chorionic villus samples were obtained in 52 cases, amniocentesis in 12 cases, and free fetal DNA in two cases. Most had a single PND, but nine had two, and one each had three or four. Hemophilia B in PND families was severe in 35 (67%), moderate in four, mild in five, and unknown in others [56](#jth12958-bib-0056){ref-type="ref"}.

*F9* sequence variants {#jth12958-sec-0015}
======================

SNVs {#jth12958-sec-0016}
----

The Exome Aggregation Consortium (ExAC) investigator coalition collected exome sequencing data from large sequencing projects on 60 706 unrelated individuals, and made the data freely available. These, along with the Database of Single Nucleotide Polymorphisms (dbSNP) and Exome Sequencing Project (ESP) frequency data, provide a useful indication of whether a variant is seen frequently in a population, and is thus more likely to be a neutral than a pathogenic variant [57](#jth12958-bib-0057){ref-type="ref"}, [58](#jth12958-bib-0058){ref-type="ref"}, [59](#jth12958-bib-0059){ref-type="ref"}. The ExAC *F9* missense variant frequency is shown in Table S2.

Mutation sex ratio {#jth12958-sec-0017}
------------------

The origin of different mutation types was investigated by Montandon *et al*., who identified different ratios of mutations of male or female origin (sex ratio of germline mutation) for different *F9* mutation types among the Swedish hemophilia B population; of 77 families, 23 had a single affected male [60](#jth12958-bib-0060){ref-type="ref"}. Mothers of 15 males were available, and of these, 13 had parents available. Three patients and 10 mothers had *de novo* mutations, and extrapolation to the Swedish population of 8.52 × 10^6^ individuals enabled the calculation that eight males and 98 females would harbor *de novo F9* mutations (\~ 10% of hemophilia B males). The mutation rate was estimated to be as follows: overall, 4.1 × 10^−6^; male, 2.1 × 10^−5^; and female, 1.9 × 10^−6^; the ratio of male/female mutation rates was 11 : 1.

Mutation mechanisms {#jth12958-sec-0018}
===================

Historically, FIX mutations were divided into classes including cross‐reacting material‐positive (reduction in activity, but not antigen, type II), reduced, and negative (parallel antigen and activity reduction, type I). Mutations can also be described as having discrepant or equivalent activity and antigen levels. Equivalent mutations reduce FIX mRNA or protein synthesis, stability, or secretion, or combinations of these properties, whereas those with discrepant hemophilia B have qualitative defects, with mutations (mostly missense) impairing functional interactions [7](#jth12958-bib-0007){ref-type="ref"}, [61](#jth12958-bib-0061){ref-type="ref"}. Sixty‐four unique mild hemophilia B mutations in mature FIX can be divided into predominantly equivalent types (23%) and predominantly discrepant types (64%). These mutations and their FIX location have been presented in detail by Rallapalli *et al*., and are not further discussed here [7](#jth12958-bib-0007){ref-type="ref"}.

'Silent' mutations {#jth12958-sec-0019}
------------------

'Silent' (synonymous) mutations can be classified as those that alter a nucleotide but not the encoded amino acid. Many have no discernible pathogenic effect, but some influence protein production, and this can occur through disruption of different processes. Splice mutations may change nucleotides at the end of exons, altering splice‐site recognition, and may also result in splice‐site creation within an exon/intron. Additionally, nucleotide changes may alter splicing regulatory protein recognition sites. Nucleotide substitution can alter mRNA stability, changing the quantity of protein produced. Codon usage alterations can influence the protein translation rate when a common tRNA anticodon is replaced by one having fewer copies, leading to protein misfolding, as illustrated by p.Val153=, which results in mild hemophilia B [62](#jth12958-bib-0062){ref-type="ref"}. These mechanisms are reviewed by Sauna *et al*. [63](#jth12958-bib-0063){ref-type="ref"}. Silent variants at FIX amino acids are listed in Table [1](#jth12958-tbl-0001){ref-type="table-wrap"}.

###### 

'Silent' variants at factor IX residues

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nucleotide change   Amino acid position (legacy numbering)   No. of patients   FIX:C (%)                                          Pathogenic mode            rs No.        ESP MAF                        ExAC MAF     ExAC allele prevalence   References
  ------------------- ---------------------------------------- ----------------- -------------------------------------------------- -------------------------- ------------- ------------------------------ ------------ ------------------------ -------------------------------------------------------------
  c.87A\>G            p.Thr29 = (--18)                         7                 \< 1--10                                           Splice donor               --            --                             --           --                       Thompson *et al*. [92](#jth12958-bib-0092){ref-type="ref"}\
                                                                                                                                                                                                                                                  Li *et al*. [93](#jth12958-bib-0093){ref-type="ref"}

  c.396A\>G           p.Val132 = (86)                          1                 NA                                                 Insufficient data          --            --                             --           --                       Mahajan *et al*. [94](#jth12958-bib-0094){ref-type="ref"}

  c.459G\>A           p.Val153 = (107)                         6                 12--20                                             Codon usage change         rs144314232   EurAm A = 0.01%                0.00001141   1/87 612                 Thompson *et al*. [92](#jth12958-bib-0092){ref-type="ref"}\
                                                                                                                                                                                                                                                  Knobe *et al*. [62](#jth12958-bib-0062){ref-type="ref"}

  c.484C\>A           p.Arg162 = (116)                         5                 3--6                                               Possible new splice site   --            --                             --           --                       Saad *et al*. [95](#jth12958-bib-0095){ref-type="ref"}

  c.519A\>C           p.Ala173 = (127)                         2                 2                                                  Splice donor               --            --                             --           --                       Unpublished

  c.519A\>G           p.Ala173 = (127)                         5                 NA                                                 Splice donor               --            --                             --           --                       Wulff *et al*. [96](#jth12958-bib-0096){ref-type="ref"}

  c.519A\>T           p.Ala173 = (127)                         1                 NA                                                 Splice donor               --            --                             --           --                       Unpublished

  c.579G\>A           p.Glu193 = (147)                         1                 NA                                                 Insufficient data          --            --                             --           --                       McGraw *et al*. [97](#jth12958-bib-0097){ref-type="ref"}

  c.711A\>G           p.Gln237 = (191)                         2                 \< 1--3                                            Possible new splice site   --            --                             --           --                       Thompson *et al*. [98](#jth12958-bib-0098){ref-type="ref"}

  c.723G\>A           p.Gln241 = (195)                         4                 \< 1--4                                            Splice acceptor            --            --                             --           --                       Chen *et al*. [92](#jth12958-bib-0092){ref-type="ref"}\
                                                                                                                                                                                                                                                  Li *et al*. [93](#jth12958-bib-0093){ref-type="ref"}

  c.738T\>C           p.Gly246 = (200)                         1                 NA                                                 Insufficient data          --            --                             --           --                       Mahajan *et al*. [94](#jth12958-bib-0094){ref-type="ref"}

  c.819T\>C           p.Val273 = (227)                         7                 \< 1--37[\*](#jth12958-note-0003){ref-type="fn"}   Neutral variant            rs1800455     EurAm C = 0.16%                0.001436     126/87 723               Koeberl *et al*. [99](#jth12958-bib-0099){ref-type="ref"}

  c.1029C\>T          p.Asn343 = (297)                         1                 NA                                                 Neutral variant            rs145026483   EurAm T = 0.64%                0.00003422   3/87 672                 Bottema *et al*. [100](#jth12958-bib-0100){ref-type="ref"}

  c.1077C\>A          p.Val359 = (313)                         1                 NA                                                 Insufficient data          --            --                             --           --                       Mahajan *et al*. [94](#jth12958-bib-0094){ref-type="ref"}

  c.1110G\>A          p.Gln370 = (324)                         1                 NA                                                 Neutral variant            rs34698779    EurAm A = 0.04% AfAm = 3.26%   0.002998     263/87 724               Unpublished

  c.1248T\>C          p.Val416 = (370)                         1                 NA                                                 Insufficient data          --            --                             --           --                       Mahajan *et al*. [94](#jth12958-bib-0094){ref-type="ref"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ESP, Exome Sequencing Project; ExAC, Exome Aggregation Consortium; FIX:C, FIX activity; MAF, minor allele frequency; NA, no data on FIX levels. Data from the *F9* mutation database, accessed 25 January 2015. \*10--37% in six cases. '=' following the amino acid position indicates no amino acid change.

John Wiley & Sons, Ltd

Ribosome readthrough of nonsense mutations {#jth12958-sec-0020}
------------------------------------------

Pinotti *et al*. analyzed spontaneous ribosome readthrough, i.e. misrecognition of premature termination codons resulting in protein production, for four *F9* nonsense mutations [64](#jth12958-bib-0064){ref-type="ref"}. *In vitro* expression demonstrated detectable FIX antigen (≤ 5% of wild‐type levels) for three of four common nonsense mutations investigated, but not for p.Arg103\*. Ribosome readthrough may enable low‐level protein production for some nonsense mutations, impacting both on disease severity and on the likelihood of inhibitor development, and sequence context appears to influence the process. Rates of inhibitor formation associated with nonsense and other mutation types are shown in Table [2](#jth12958-tbl-0002){ref-type="table-wrap"}.

###### 

Association of inhibitors with mutation type in patients listed in the *F9* mutation database

  Mutation type        No. of patients with inhibitors   Total no. of patients with the same mutation   Patients with inhibitors (%)
  -------------------- --------------------------------- ---------------------------------------------- --------------------------------------------
  Large deletion       30                                69                                             43
  Nonsense             23                                229                                            10
  Frameshift           5                                 5                                              --[\*](#jth12958-note-0004){ref-type="fn"}
  Splice               2                                 6                                              --[\*](#jth12958-note-0004){ref-type="fn"}
  Insertion/deletion   1                                 1                                              --[\*](#jth12958-note-0004){ref-type="fn"}
  Missense             1                                 1                                              --[\*](#jth12958-note-0004){ref-type="fn"}
  Total                62                                311                                            20

Mutation details are shown in Table S3. Mutation data are from [6](#jth12958-bib-0006){ref-type="ref"}. For large deletions, breakpoints may not have been identified, and deletions of the same exons may have different intronic sequence breakpoints. \*Numbers too small for percentage to be relevant.
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Hemophilia B Leyden {#jth12958-sec-0021}
-------------------

In 1970, a new form of hemophilia B was recognized [65](#jth12958-bib-0065){ref-type="ref"}, in which FIX:C levels rise rapidly (up to 5 IU dL^−1^ per year) from puberty onwards, reaching the lower normal range in many cases. Depending on the mutation, some individuals are initially affected by severe hemophilia B, whereas others have a milder phenotype [66](#jth12958-bib-0066){ref-type="ref"}. Patients may become clotting factor‐independent by early adulthood [67](#jth12958-bib-0067){ref-type="ref"}. The phenotype is seen in 1.9% of patients in the *F9*db (P.M. Rallapalli, personal communication). A short region of the proximal promoter (HGVS c.‐50 to c.‐18, legacy −27 to +13) contains binding sites for three transcription factors: hepatic nuclear factor 4α from c.‐49 (−20), CCAAT enhancer‐binding protein from c.‐19 (+10), and the recently identified ONECUT1 (also called HNF6) and the related ONECUT2, which binds less well, with binding centered around c.‐35_34 (−5/−6) [67](#jth12958-bib-0067){ref-type="ref"}, [68](#jth12958-bib-0068){ref-type="ref"}. Disruption of these sites by point mutation can reduce transcription factor binding during infancy/childhood, but the postpubertal FIX level rise induced by growth hormone production still occurs as in other pubertal children [69](#jth12958-bib-0069){ref-type="ref"}. Mutations are listed in Table [3](#jth12958-tbl-0003){ref-type="table-wrap"}.

###### 

Hemophilia B Leyden mutations

  HGVS nucleotide no.   Legacy nucleotide no.   FIX:C (%)[\*](#jth12958-note-0005){ref-type="fn"}   No. of patients
  --------------------- ----------------------- --------------------------------------------------- -----------------
  c.‐50T\>G             −21                     0--10                                               3
  c.‐49T\>A             −20                     0--60                                               3
  c.‐48G\>C             −19                     3                                                   2
  c.‐35G\>A             −6                      0--25, 13--70                                       31
  c.‐35G\>C             −6                      1--30                                               5
  c.‐34A\>T             −5                      3                                                   3
  c.‐24T\>A             6                       0--8, 0--37                                         4
  c.‐22T\>C             8                       0--60                                               4
  c.‐22delT             8                       5                                                   1
  c.‐21C\>G             9                       NA                                                  1
  c.‐18A\>G             12                      2.5--28, 0--60                                      11
  c.‐18delA             12                      0--60                                               1

FIX:C, FIX activity; HGVS, Human Genome Variation Society; NA, not available. Mutation data from the *F9* mutation database [6](#jth12958-bib-0006){ref-type="ref"}. \*Initial and most recent FIX:C level.

John Wiley & Sons, Ltd

Early reports suggested that females did not experience the same FIX level rise, but a recent report documented symptomatic hemophilia B carrier sisters who had elevated postpubertal levels [70](#jth12958-bib-0070){ref-type="ref"}. Two male relatives had childhood FIX levels of 1 IU dL^−1^ and 2 IU dL^−1^, which rose to 24 IU dL^−1^ at 21 years in one individual, and to 45 IU dL^−1^ in an uncle only analyzed in adulthood. Prepubertal carrier levels (11 IU dL^−1^ and 17 IU dL^−1^) rose to 21 IU dL^−1^ (16 years) and 35 IU dL (14 years). Their elevated levels are consistent with work in mice [69](#jth12958-bib-0069){ref-type="ref"} demonstrating that an increased FIX level is associated with rising postpubertal growth hormone levels rather than testosterone, as previously postulated.

Recurrent mutations (RMs) or identity by descent (IBD)? {#jth12958-sec-0022}
-------------------------------------------------------

When little treatment was available for hemophilia B, it was estimated that mutations causing severe disease would last for only two to four generations before being lost through the patient\'s death prior to reproduction. *De novo* mutations are more common in severe than in mild hemophilia B, but may involve the same residues, leading to RMs that are not associated with specific haplotypes or ethnic groups. As patients with moderate/mild disease often lived to reproduce, mutations were transmitted through the population, and sometimes resulted in a founder effect, whereby several individuals shared the same mutation through IBD; this is seen particularly in isolated populations.

Mukherjee *et al*. analyzed mutations occurring at the CpG dinucleotide mutation hotspot in individuals reported in the *F9*db, and identified several different haplotypes for many RMs [71](#jth12958-bib-0071){ref-type="ref"}. For example, in 2003, p.Thr342Met had 106 *F9*db entries on 15 apparently different haplotypes. Bottema *et al*. studied 38 patients with *F9* CpG dinucleotide mutations, and, using six SNVs, found that patients with severe hemophilia B were more likely to have RMs than IBD [72](#jth12958-bib-0072){ref-type="ref"}. More recently, Hallden *et al*. investigated IBD in the entire Swedish hemophilia B population, and found that, that among all 86 families, substitution mutations identified in more than one family were present in 47 of 77 families (61%). Haplotyping using 74 markers in and flanking *F9* showed that 24 families had IBD mutations, the majority of which had mild disease. Mutation ages were estimated at 2--23 generations. The remaining 23 families appeared to have RMs [73](#jth12958-bib-0073){ref-type="ref"}.

Analysis of the *F9* mutation rate suggests that the introduction of modern chemicals does not appear to have altered the rate [74](#jth12958-bib-0074){ref-type="ref"}, and that the mutation rate is comparable among different population groups [75](#jth12958-bib-0075){ref-type="ref"}, [76](#jth12958-bib-0076){ref-type="ref"}, [77](#jth12958-bib-0077){ref-type="ref"}. Germline *F9* mutations therefore largely result from endogenous processes rather than exogenous mutagens.

More than one mutation {#jth12958-sec-0023}
----------------------

In a review of the *F9*db (3656 patients), 49 were reported to have multiple mutations (1.3%; P.M. Rallapalli, personal communication). Forty‐six had two candidate mutations, two had three, and one had four. Among these variants, 11 individuals had silent changes at six different positions (22%), seven had c.391+7A\>G, six had c.839‐20dupA (reported as c.839‐20_839‐19insA), and two had the common exon 6 variant c.580A\>G (p.Ala194Thr). Variant frequencies in dbSNP, along with amino acid conservation and splice‐site prediction, suggest that pathogenicity is unlikely (c.391+7A\>G, minor allele frequency \[MAF\] in African Americans, 0.13; c.839‐20dupA, MAF in European Americans, 0.0164; c.580A\>G, MAF in European Americans, 0.298), leaving 20 patients with two possible mutations (0.55%). Ghosh *et al*. examined 103 patients, and identified eight with two mutations (7.8%, including two related individuals) [78](#jth12958-bib-0078){ref-type="ref"}. None of the variants was seen in either ExAC or dbSNP [71](#jth12958-bib-0071){ref-type="ref"}, [72](#jth12958-bib-0072){ref-type="ref"}.

Inhibitors {#jth12958-sec-0024}
==========

Inhibitory antibodies are high‐affinity polyclonal antibodies that neutralize the procoagulant activity of a coagulation factor. Inhibitors are much less common in patients with hemophilia B than in those with hemophilia A. They are reported in 2% of patients in the *F9*db, almost exclusively in patients with severe disease [6](#jth12958-bib-0006){ref-type="ref"}, and in 2% of 3785 patients with hemophilia B in the UDC project [2](#jth12958-bib-0002){ref-type="ref"}. Most occur in patients with large deletions or nonsense mutations, and they occur less commonly in patients with small deletions/insertion--deletions, splice mutations, and a single *F9*db missense mutation (p.Gln237Lys) [79](#jth12958-bib-0079){ref-type="ref"}, plus another from the USA (p.Gln241His) [80](#jth12958-bib-0080){ref-type="ref"}. Table [2](#jth12958-tbl-0002){ref-type="table-wrap"} summarizes mutation types in patients with hemophilia B and inhibitors, and Table S3 provides further detail.

In contrast to hemophilia A, where anaphylaxis is rare, anaphylaxis can occur in severe hemophilia B, particularly during early treatment, and several guidelines therefore suggest that the first 20 days of FIX concentrate exposure should take place in hospital. Several factors may contribute to anaphylaxis risk. In comparison with FVIII, FIX is relatively small and readily diffuses into extravascular spaces. Its plasma concentration of 5 mg mL^−1^ is much higher (FVIII 0.1 mg mL^−1^), and FIX treatment doses contain more protein than used for hemophilia A. Lack of tolerance to FIX in patients with mutations resulting in complete absence of FIX production, along with a high therapeutic dose and extravascular dispersion, may contribute to hypersensitivity and inhibitor development [81](#jth12958-bib-0081){ref-type="ref"}. In contrast to antibodies against FVIII, antibodies against FIX may form circulating immune complexes. These can initiate anaphylaxis when the individual is re‐exposed to FIX concentrate.

The ISTH Scientific and Standardization Committee international FIX inhibitor registry (1997--2006) analyzed 94 patients with severe hemophilia B and an inhibitor [82](#jth12958-bib-0082){ref-type="ref"}. Thirty‐two of 94 patients underwent genetic analysis demonstrating that large deletions and nonsense mutations were associated with both inhibitor development and anaphylaxis. Individuals with complete gene deletions had the highest risk; 56 of 94 had experienced anaphylaxis (60%), with the risk being stated as ≥ 26% in individuals with complete gene deletions. Nephrotic syndrome (kidney disorder characterized by proteinuria, hypoalbuminemia, and edema) affected the same group, with 13 patients developing this complication (14%). Nephrotic syndrome developed while patients were receiving immune tolerance induction therapy [82](#jth12958-bib-0082){ref-type="ref"}.

Pathogenicity prediction {#jth12958-sec-0025}
========================

When mutation analysis is undertaken, previously identified mutations may be found. Documenting their pathogenicity is often straightforward, particularly when the variant has been seen in other patients with similar FIX levels. Where internet searching does not identify the variant in other patients, *in silico* pathogenicity prediction can help to determine whether the variant is likely to be pathogenic. Guideline documents on assessing predicted pathogenicity have been published by the Association for Clinical Genetic Science [83](#jth12958-bib-0083){ref-type="ref"} and the American College of Medical Genetics [84](#jth12958-bib-0084){ref-type="ref"}, and incorporate searching for reports on population frequency; for missense variants, the parameters examined include extent of conservation across a range of species; for possible splice variants, the use of different algorithm types for splice‐site prediction; functional studies, e.g. *in vitro* expression of a missense variant; and mRNA analysis to determine the effects of splice mutations and cosegregation of the variant with disease. A specific pathogenicity prediction tool has been designed for hemophilia [85](#jth12958-bib-0085){ref-type="ref"}, and modeling of hydrogen bond changes suggests that these bonds are less frequently affected in mild than in severe hemophilia B [86](#jth12958-bib-0086){ref-type="ref"}. Modeling protein structure can help in understanding the impact of amino acid substitution [6](#jth12958-bib-0006){ref-type="ref"}, [7](#jth12958-bib-0007){ref-type="ref"}, [87](#jth12958-bib-0087){ref-type="ref"}. Table S4 lists suggested resources.

External quality assessment (EQA) {#jth12958-sec-0026}
=================================

Genetic diagnostic services are often required by their laboratory accreditation to participate in EQA. The UK National External Quality Assessment Survey (UK NEQAS) runs a scheme for Molecular Genetics of Heritable Bleeding Disorders, and arranges two surveys annually on the analysis of hemophilia A, hemophilia B, or von Willebrand disease [88](#jth12958-bib-0088){ref-type="ref"}. The analyses resemble a diagnostic referral, posing a specific question regarding the patient, frequently accompanied by a relative. Reports are scored on: (i) relevant referrer and patient details; (ii) identification of correct genotype; and, importantly, (iii) correct interpretation of the results' significance for the patient and family. General recommendations are returned to all participants, with specific feedback on each laboratory\'s performance. Two points are awarded for each of the survey areas, and participants must gain at least one point in each area to pass the exercise. The scheme has seen rapid improvement in report format and essential inclusions from new scheme participants [89](#jth12958-bib-0089){ref-type="ref"}, [90](#jth12958-bib-0090){ref-type="ref"}.

Hemophilia B gene therapy {#jth12958-sec-0027}
=========================

A successful trial of hemophilia B gene therapy has been undertaken in London, with adeno‐associated virus 8 as an *F9* vector. Ten patients were enrolled: an initial six for a phase 1 dose‐escalation study, with two patients each receiving low, intermediate or high doses of vector genome (2 × 10^11^ kg^--1^ to 2 × 10^12^ kg^--1^); plus four further patients given the high dose. All had extensive clinical and laboratory follow‐up after a single intravenous vector infusion. All 10 patients showed rises in FIX:C level of 1--6% over a median of 3.2 years. The high‐dose group of six patients had FIX:C levels of 5.1% ± 1.7%. FIX concentrate use was significantly reduced for all patients following treatment (median 2613 IU kg^−1^ per year in the year before vector infusion; median 206 IU kg^−1^ per year in the year following infusion; *P* = 0.002). The median number of bleeding episodes for all patients was 15.5 in the year prior to infusion, but only 1.5 in the year following infusion, i.e. a 90% reduction (*P* = 0.009). Of seven patients previously receiving prophylaxis, four discontinued this treatment. Alanine aminotransferase levels were transiently raised in four of six high‐dose patients, but resolved with prednisolone treatment over a median of 5 days, and no late toxic effects were reported [91](#jth12958-bib-0091){ref-type="ref"}. The study provides very encouraging data on the future of gene therapy in hemophilia.

Conclusion {#jth12958-sec-0028}
==========

Hemophilia B is one of the most heavily studied of genetic disorders, and many thousands of patients have had their mutations identified. Mutations are detected in \> 97% of cases, but remain elusive in a few. Mode of pathogenicity has been explored through *in vitro* expression for a minority of mutations. Knowledge of the mutation can facilitate inhibitor risk prediction, carrier detection, and PND for affected families.
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